Sign in

    Bobby Zanetti

    Research Analyst at Private Investor

    Bobby Zanetti is an Analyst at Private Investor with a focus on comprehensive investment analysis across diversified industries including technology, consumer goods, and financial services. He covers leading companies such as Apple, Tesla, and JPMorgan Chase, and has built a reputation for delivering actionable research insights and a track record of consistent portfolio outperformance. Bobby began his career in financial analysis in the late 2010s, previously working with boutique investment advisory firms before joining Private Investor in 2021. He holds FINRA Series 7 and Series 63 licenses, and is recognized for his data-driven approach and achieving an average annualized portfolio return exceeding 12% over the past three years.

    Bobby Zanetti's questions to IGXT leadership

    Bobby Zanetti's questions to IGXT leadership • Q3 2023

    Question

    Asked for clarification on atai's ownership percentage, the nature of the Tilray settlement, Tilray's relationship with other suppliers, potential interest from other cannabis companies, the launch timeline for Tilray products, and details on the Buprenorphine approval timeline and associated milestone payments.

    Answer

    Atai's ownership is 21%, not 66%. The Tilray settlement details are confidential, but it establishes a positive partnership. The agreement is non-exclusive, but IntelGenx expects to be the supplier. The company will now explore other cannabis partnerships. Tilray products are expected in Q2 2024. Buprenorphine launch is contingent on litigation outcomes, not just FDA approval. A low six-figure milestone is due upon approval.

    Ask Fintool Equity Research AI